Sanofi: Hemophilia B trials
The registry lists 10 Hemophilia B studies with Sanofi as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 3Phase 2 1Phase 3 6No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without InhibitorsCompletedNCT03417245Phase 3Results posted
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With InhibitorsCompletedNCT03417102Phase 3Results posted
- An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or BCompletedNCT02554773Phase 1/2Results posted
- Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia BCompletedNCT02234310Phase 3Results posted
- Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia BCompletedNCT01440946Phase 3Results posted
- Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia BCompletedNCT01425723Phase 3Results posted
- Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia BCompletedNCT01027364Phase 3Results posted
- Fc factOrs and Real-World hemophiliA Patient-ReporteD OutcomesTerminatedNCT02392156
- A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B PatientsCompletedNCT02035605Phase 1
- Phase I/IIa Study of FIXFc in Hemophilia B PatientsCompletedNCT00716716Phase 1